This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock OBLN vs. OSUR, TLSI, CATX, UTMD, CVRX, LUCD, RCEL, SGHT, ARAY, and ANIKShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include OraSure Technologies (OSUR), TriSalus Life Sciences (TLSI), Perspective Therapeutics (CATX), Utah Medical Products (UTMD), CVRx (CVRX), Lucid Diagnostics (LUCD), AVITA Medical (RCEL), Sight Sciences (SGHT), Accuray (ARAY), and Anika Therapeutics (ANIK). These companies are all part of the "medical" sector. Obalon Therapeutics vs. OraSure Technologies TriSalus Life Sciences Perspective Therapeutics Utah Medical Products CVRx Lucid Diagnostics AVITA Medical Sight Sciences Accuray Anika Therapeutics OraSure Technologies (NASDAQ:OSUR) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership. Does the MarketBeat Community believe in OSUR or OBLN? OraSure Technologies received 307 more outperform votes than Obalon Therapeutics when rated by MarketBeat users. Likewise, 68.87% of users gave OraSure Technologies an outperform vote while only 46.42% of users gave Obalon Therapeutics an outperform vote. CompanyUnderperformOutperformOraSure TechnologiesOutperform Votes55368.87% Underperform Votes25031.13% Obalon TherapeuticsOutperform Votes24646.42% Underperform Votes28453.58% Do insiders & institutionals have more ownership in OSUR or OBLN? 93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are held by institutional investors. 3.9% of OraSure Technologies shares are held by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer OSUR or OBLN? OraSure Technologies currently has a consensus price target of $3.00, indicating a potential upside of 1.69%. Given OraSure Technologies' stronger consensus rating and higher possible upside, analysts clearly believe OraSure Technologies is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OraSure Technologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is OSUR or OBLN more profitable? OraSure Technologies has a net margin of 5.07% compared to Obalon Therapeutics' net margin of -776.76%. OraSure Technologies' return on equity of 3.55% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OraSure Technologies5.07% 3.55% 3.23% Obalon Therapeutics -776.76%-161.38%-83.58% Which has higher valuation & earnings, OSUR or OBLN? OraSure Technologies has higher revenue and earnings than Obalon Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOraSure Technologies$161.63M1.37$53.65M-$0.42-7.02Obalon Therapeutics$1.59M30.95-$12.33MN/AN/A Which has more risk and volatility, OSUR or OBLN? OraSure Technologies has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Does the media prefer OSUR or OBLN? In the previous week, OraSure Technologies had 4 more articles in the media than Obalon Therapeutics. MarketBeat recorded 4 mentions for OraSure Technologies and 0 mentions for Obalon Therapeutics. OraSure Technologies' average media sentiment score of 1.04 beat Obalon Therapeutics' score of 0.00 indicating that OraSure Technologies is being referred to more favorably in the media. Company Overall Sentiment OraSure Technologies Positive Obalon Therapeutics Neutral SummaryOraSure Technologies beats Obalon Therapeutics on 14 of the 16 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.21M$4.44B$5.42B$8.41BDividend YieldN/A45.22%5.28%4.16%P/E Ratio-3.6429.1227.0519.79Price / Sales30.9573.65406.30134.05Price / CashN/A51.0838.2534.64Price / Book8.185.706.744.50Net Income-$12.33M$67.51M$3.23B$248.30M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$4.91+8.1%N/A+1,863.2%$49.21M$1.59M-3.642OSUROraSure Technologies3.3372 of 5 stars$2.52-1.9%$3.00+19.0%-37.6%$188.50M$161.63M16.80840Positive NewsTLSITriSalus Life Sciences2.8773 of 5 stars$5.56+3.9%$10.93+96.6%-24.2%$179.43M$32.14M-2.23106Short Interest ↑Gap DownCATXPerspective Therapeutics3.5106 of 5 stars$2.39-4.8%$12.50+423.0%-81.4%$177.41M$1.43M0.0070News CoverageUTMDUtah Medical Products3.3443 of 5 stars$53.76+0.2%N/A-19.5%$174.61M$39.27M13.61180Positive NewsDividend AnnouncementCVRXCVRx2.5761 of 5 stars$6.67+0.3%$14.50+117.4%-4.7%$173.91M$52.87M-2.48160Positive NewsShort Interest ↑Gap DownLUCDLucid Diagnostics2.7917 of 5 stars$1.59+19.5%$3.50+120.1%+56.7%$172.02M$4.17M-1.3970Short Interest ↑Gap UpHigh Trading VolumeRCELAVITA Medical1.2391 of 5 stars$6.28-1.9%$17.25+174.7%-41.6%$166.01M$71.66M-2.63130Short Interest ↑SGHTSight Sciences2.2429 of 5 stars$3.20-2.4%$4.02+25.5%-43.4%$165.43M$78.11M-3.14210News CoveragePositive NewsGap DownARAYAccuray2.6001 of 5 stars$1.57-0.6%N/A-12.4%$161.73M$465.25M-31.401,040Analyst UpgradeGap DownANIKAnika Therapeutics4.2862 of 5 stars$11.24-4.5%$21.33+89.8%-56.3%$161.19M$117.05M-1.69300Positive News Related Companies and Tools Related Companies OSUR Competitors TLSI Competitors CATX Competitors UTMD Competitors CVRX Competitors LUCD Competitors RCEL Competitors SGHT Competitors ARAY Competitors ANIK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBLN) was last updated on 6/1/2025 by MarketBeat.com Staff From Our PartnersTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredThe “supermetal” that could power AIWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Buffett Indicator is screaming, “sell stocks, buy gold”A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBLN Stock Free OBLN Stock Alerts